Small Molecule Api Market

Small Molecule API Market: APEJ Projected to be the Most Lucrative Regional Market During the Forecast Period: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027

Ask The Analyst Customization Available Request Methodology

Global scenario of the small molecule API market – moderate growth rate observed

The global small molecule API market is anticipated to grow at a moderate rate to register a CAGR of 4.9% during the period of forecast, 2017-2027. There are several aspects that govern the growth rate of the global small molecule API market. The key drivers fuelling the growth of the market are factors such as rise in small molecule API growth, the HPAPI witnessing higher boost in growth rate, and the pharmerging countries being explored as alternative sourcing destinations. Trends such as the sourcing of the APIs done from Indian pharmaceutical manufacturers based in the U.S and higher investment in infrastructural facilities in order to raise the in-house production also contribute to the growth of the global small molecule API market. Moreover, owing to these drivers and trends, there are certain opportunities that lurk within the global small molecule API market. To name a few – the growth in healthcare spending in developing nations such as Asia Pacific and other regions and expansion with respect to product offerings as well as reduction in the costs involved.

Asia Pacific excluding Japan to grow at full speed and gain high market share

Asia Pacific excluding Japan (APEJ) reflects higher speed by registering a growth rate of 5.8% during the forecast period 2017 to 2025. The Asian countries hold significant revenue share in the entire market. Most of the anti-inflammatory drugs as well as antibiotic drugs are produced in the Asian counties, with China and India topping the list. Almost 80% of the total antibiotic APIs are produced in China and India and most of these APIs are outsourced to developed regions such as Europe and North America. The main reasons for this to be possible is the abundant availability of raw material needed to produce APIs, and the availability of low cost labour in India and China. Additionally, these regions enjoy a favourable regulatory assistance along with low taxation policies in order to establish API manufacturing businesses. Also, a large patient population consumes non-controlled drugs, which makes Asia Pacific excluding Japan experience a higher in-house API consumption. The APEJ region also reflects a high market attractiveness and higher market share of almost 34% estimated to be held in 2017. This percentage is expected to rise even higher by the end of 2027, following the major trends that push the growth of the global small molecule API market in the APEJ region.

The pharma companies in India had filed DMFs making India the leading country in DMF filing. This infers that in the near future, majority of the API manufacturing contracts from U.S. based companies would be awarded to India based companies. Moreover, the rapid rise in the Indian generics market will also fuel the API market growth in this region.

Trend analysis in the APEJ market – raising the bar of growth in the region

The Asia Pacific excluding Japan region is all set to experience a tremendous growth rate during the forecast period. The APEJ small molecule API market is expected to show a high figure of more than US$ 52 Bn by the end of 2027 and dominate the global market. The main reason for this growth is the high outsourcing in this region. Developing nations of China and India lead by SMEs. The production in these countries is rising owing to limited regulatory coverage. Also, the in-house consumption in India is higher, which has resulted in increased focus on the manufacturing of APIs in India.

The distribution network is also extensive in the overseas markets especially in regions such as Europe, United States and South Africa. Another factor supporting the statement that APEJ is experiencing higher growth is – Indian companies manufacturing APIs are taking advantage of the export opportunities especially in the Latin America region. All these trends are aiding the facts that are favourable for the growth of the small molecule API market in the APEJ region. The region that is the most growing and anticipated to grow even further is China, which shows a higher growth rate to register a CAGR of 6.9% followed by India.

The in-depth and thorough report titled “Small Molecule API Market: Global Industry Analysis 2012-2016 & Opportunity Assessment 2017-2027” gives the reader a feel and flavour of the market understanding with a wide overview of the market thereby supporting decision making and slating different strategies as and when required.

An exhaustive market research report on the small molecule API market offers weighted analysis of the entire market. Focussing on the major segments and covering all factors that have an influence over the market helps predict the growth rate of the market in the particular regions. Below sketched is the market taxonomy that covers all the segments of the global small molecule API market.

Molecule

Production

Application

Therapeutic Area

Region

  • Standard API

  • High Potency API

  • Captive/In-House

  • Outsourced

  • Clinical

  • Commercial

  • Cardiovascular Diseases

  • Respiratory Disorders

  • Infectious Diseases

  • Metabolic Disorders

  • Oncology

  • Immunology

  • Neurology

  • Urology

  • Dermatology

  • Ophthalmology

  • General Health

  • Others

  • North America

  • Latin America

  • Western Europe

  • Eastern Europe

  • Asia Pacific Excluding Japan

  • Japan

  • Middle East & Africa

 This research study on the small molecule API market delivers value to the reader by making them aware about the past and present scenario of the market. The study also uncovers predictions of the future thereby giving an inkling about the small molecule API market scenario 10 years down the line. It emphasises on the various intelligence acumen such as pricing, product portfolio of various key players present in the market, distribution channel analysis, key developments, trends in present and future, a complete SWOT analysis along with PESTLE analysis and also analysis of the important regions assessed. The study covers revenue generated by API manufacturing including in-house and outsourced manufacturing. The report analyses the demand from in-house production as well as outsourced API production. These insights help plan future decisions and strategic moves that could be easily executed owing to the actionable nature of the understandings present in the report.

An effective research process to ensure maximum proficiency

At Future Market Insights, the analysts follow a rock-solid research process to allow minimum deviations in the research and reach maximum accuracy. In order to get a 3600 view of the market, a strong secondary research is carried out. Assistance of secondary paid sources is just enough to get going in the correct direction. The secondary research gives a direction to the market definition based on which several primary interviews are carried out. Key decision makers from several companies within the market are interviewed as well as opinions of market observers are gathered. The data collected from the secondary sources and the corresponding data gathered by primaries is collated and each data point is verified while conversing with the market experts. The best part of this unique methodology is that the data so gathered undergoes evaluation and validation again and again which makes the intelligence extremely accurate giving a realistic shape to the market scenario. A holistic view of the market thus ensures timely and effective strategies to be implemented owing to the data crunching done with reduced or eliminated deviations from the actual face value of the market.

Competition analysis

The research study provides a separate chapter on the competitive landscape, which covers all the major players in the market, along with their details. Facets such as product portfolio analyses, mergers and acquisitions, developments and innovations, key trends followed, market shares and revenues, geographical spread and expansion plans, marketing strategies and pricing intelligence, etc. of the key players are focussed upon. This helps the reader freeze their own milestones and the various strategic moves required to achieve those milestones. The key players include all the tier companies that have a firm hold over the market and can be said to be the face of the market. The intelligence provided on these players enables the reader to understand the “not-to-do” aspects and how to set foot in the right direction.

The key value additions that the report offers:

  • The entire report gives credible information with an unbiased interpretation, considering all the possible angles and giving it a holistic view
  • The report gives details about each segment present in the market with respect to all important geographies
  • The research study enables unparalleled accuracy owing to the use of a robust research methodology
  • The research on the past and the present scenario in the global market can give actionable insights on the future; a separate dedicated section on the forecasts helps the reader analyse present moves and predict future actions
  • In-depth analysis covers everything giving justice to each segment involved
  • The trends, developments, innovations, restraints and challenges faced by every facet is also covered giving a total briefing about the market and uncovering the possible loop holes

Small Molecule Api Market Reports - Table of Contents

1. Executive Summary

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Small Molecule Active Pharmaceutical Ingredient Market View Point 

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Regulatory Scenario

3.4. Pipeline Assessment

4. North America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

4.1. Introduction

4.2. Pestle Analysis

4.3. Regional Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Trends

4.4. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

4.4.1. U.S.

4.4.2. Canada

4.5. Market Size (US$ Mn) Forecast By Country, 2017–2027

4.5.1. U.S.

4.5.2. Canada

4.6. Historical Market Size (US$ Mn) Trend Analysis By Molecule Type, 2012–2016

4.6.1. Standard API

4.6.2. High Potency API

4.7.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

4.7.1. Standard API

4.7.2. High Potency API

4.8. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

4.8.1. In-House

4.8.2. Outsourced 

4.9. Market Size (US$ Mn)  Forecast By Production, 2017–2027

4.9.1. In-House

4.9.2. Outsourced 

4.10. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

4.10.1. Clinical 

4.10.2. Commercial 

4.11. Market Size (US$ Mn)  Analysis By Application, 2017–2027

4.11.1. Clinical 

4.11.2. Commercial 

4.12. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

4.12.1. Cardiovascular

4.12.2. Respiratory

4.12.3. Infectious

4.12.4. Metabolic

4.12.5. Oncology

4.12.6. Immunology

4.12.7. Neurology

4.12.8. Urology

4.12.9. Dermatology

4.12.10. Ophthalmology

4.12.11. General Health

4.12.12. Others

4.13.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

4.13.1. Cardiovascular

4.13.2. Respiratory

4.13.3. Infectious

4.13.4. Metabolic

4.13.5. Oncology

4.13.6. Immunology

4.13.7. Neurology

4.13.8. Urology

4.13.9. Dermatology

4.13.10. Ophthalmology

4.13.11. General Health

4.13.12. Others

4.14. Drivers and Restraints: Impact Analysis

4.15. Market Attractiveness Analysis

4.15.1. By Country

4.15.2. By Molecule Type

4.15.3. By Production

4.15.4. By Application

4.15.5. By Therapeutic Area

4.16. Key Representative Market Participants

4.17. Market Presence (Intensity Map)

5. Latin America Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

5.1. Introduction

5.2. Regional Market Dynamics

5.2.1. Drivers

5.2.2. Restraints

5.2.3. Trends

5.3. Historical Market Size (US$ Mn)  Trend Analysis By Country, 2012–2016

5.3.1. Brazil

5.3.2. Mexico

5.3.3. Rest of Latin America

5.4. Market Size (US$ Mn)  Forecast By Country, 2017–2027

5.4.1. Brazil

5.4.2. Mexico

5.4.3. Rest of Latin America

5.5. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

5.5.1. Standard API

5.5.2. High Potency API

5.6.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

5.6.1. Standard API

5.6.2. High Potency API

5.7. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

5.7.1. In-House

5.7.2. Outsourced 

5.8. Market Size (US$ Mn)  Forecast By Production, 2017–2027

5.8.1. In-House

5.8.2. Outsourced 

5.9. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

5.9.1.  Clinical 

5.9.2. Commercial 

5.10. Market Size (US$ Mn)  Analysis By Application, 2017–2027

5.10.1. Clinical 

5.10.2. Commercial 

5.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

5.11.1. Cardiovascular

5.11.2. Respiratory

5.11.3. Infectious

5.11.4. Metabolic

5.11.5. Oncology

5.11.6. Immunology

5.11.7. Neurology

5.11.8. Urology

5.11.9. Dermatology

5.11.10. Ophthalmology

5.11.11. General Health

5.11.12. Others

5.12.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

5.12.1. Cardiovascular

5.12.2. Respiratory

5.12.3. Infectious

5.12.4. Metabolic

5.12.5. Oncology

5.12.6. Immunology

5.12.7. Neurology

5.12.8. Urology

5.12.9. Dermatology

5.12.10. Ophthalmology

5.12.11. General Health

5.12.12. Others

5.13. Drivers and Restraints: Impact Analysis

5.14. Market Attractiveness Analysis

5.14.1. By Country

5.14.2. By Molecule Type

5.14.3. By Production

5.14.4. By Application

5.14.5. By Therapeutic Area

5.15. Key Representative Market Participants 

5.16. Market Presence (Intensity Map)

6. Western Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

6.1. Introduction

6.2. Regional Market Dynamics

6.2.1. Drivers

6.2.2. Restraints

6.2.3. Trends

6.3. Historical Market Size (US$ Mn)  Trend Analysis By Country, 2012–2016

6.3.1. Germany

6.3.2. Italy

6.3.3. France

6.3.4. Spain

6.3.5. U.K.

6.3.6. BENELUX

6.3.7. Nordic

6.3.8. Rest of Western Europe

6.4. Market Size (US$ Mn)  Forecast By Country, 2017–2027

6.4.1. Germany

6.4.2. Italy

6.4.3. France

6.4.4. Spain

6.4.5. U.K.

6.4.6. BENELUX

6.4.7. Nordic

6.4.8. Rest of Western Europe

6.5. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

6.5.1. Standard API

6.5.2. High Potency API

6.6.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

6.6.1. Standard API

6.6.2. High Potency API

6.7. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

6.7.1. In-House

6.7.2. Outsourced 

6.8. Market Size (US$ Mn)  Forecast By Production, 2017–2027

6.8.1. In-House

6.8.2. Outsourced 

6.9. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

6.9.1. Clinical 

6.9.2. Commercial 

6.10. Market Size (US$ Mn)  Analysis By Application, 2017–2027

6.10.1. Clinical 

6.10.2. Commercial 

6.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

6.11.1. Cardiovascular

6.11.2. Respiratory

6.11.3. Infectious

6.11.4. Metabolic

6.11.5. Oncology

6.11.6. Immunology

6.11.7. Neurology

6.11.8. Urology

6.11.9. Dermatology

6.11.10. Ophthalmology

6.11.11. General Health

6.11.12. Others

6.12.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

6.12.1. Cardiovascular

6.12.2. Respiratory

6.12.3. Infectious

6.12.4. Metabolic

6.12.5. Oncology

6.12.6. Immunology

6.12.7. Neurology

6.12.8. Urology

6.12.9. Dermatology

6.12.10. Ophthalmology

6.12.11. General Health

6.12.12. Others

6.13. Drivers and Restraints: Impact Analysis

6.14. Market Attractiveness Analysis

6.14.1. By Country

6.14.2. By Molecule Type

6.14.3. By Production

6.14.4. By Application

6.14.5. By Therapeutic Area

6.15. Key Representative Market Participants

6.16. Market Presence (Intensity Map)

7. Eastern Europe Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

7.1. Introduction

7.2. Historical Market Size (US$ Mn)  Trend Analysis By Country, 2012–2016

7.2.1. Russia

7.2.2. Poland

7.2.3. Rest of Eastern Europe

7.3. Market Size (US$ Mn)  Forecast By Country, 2017–2027

7.3.1. Russia

7.3.2. Poland

7.3.3. Rest of Eastern Europe

7.4. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

7.4.1. Standard API

7.4.2. High Potency API

7.5.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

7.5.1. Standard API

7.5.2. High Potency API

7.6. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

7.6.1. In-House

7.6.2. Outsourced 

7.7. Market Size (US$ Mn)  Forecast By Production, 2017–2027

7.7.1. In-House

7.7.2. Outsourced 

7.8. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

7.8.1. Clinical 

7.8.2. Commercial 

7.9. Market Size (US$ Mn)  Analysis By Application, 2017–2027

7.9.1. Clinical 

7.9.2. Commercial 

7.10. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

7.10.1. Cardiovascular

7.10.2. Respiratory

7.10.3. Infectious

7.10.4. Metabolic

7.10.5. Oncology

7.10.6. Immunology

7.10.7. Neurology

7.10.8. Urology

7.10.9. Dermatology

7.10.10. Ophthalmology

7.10.11. General Health

7.10.12. Others

7.11.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

7.11.1. Cardiovascular

7.11.2. Respiratory

7.11.3. Infectious

7.11.4. Metabolic

7.11.5. Oncology

7.11.6. Immunology

7.11.7. Neurology

7.11.8. Urology

7.11.9. Dermatology

7.11.10. Ophthalmology

7.11.11. General Health

7.11.12. Others

7.12. Drivers and Restraints: Impact Analysis

7.13. Market Attractiveness Analysis

7.13.1. By Country

7.13.2. By Molecule Type

7.13.3. By Production

7.13.4. By Application

7.13.5. By Therapeutic Area

7.14. Key Representative Market Participants

7.15. Market Presence (Intensity Map)

8. Asia Pacific excluding Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

8.1. Introduction

8.2. Regional Market Dynamics

8.2.1. Drivers

8.2.2. Restraints

8.2.3. Trends

8.3. Historical Market Size (US$ Mn)  Trend Analysis By Country, 2012–2016

8.3.1. China

8.3.2. India

8.3.3. ASEAN

8.3.4. Australia and New Zealand

8.3.5. Rest of APEJ

8.4. Market Size (US$ Mn)  Forecast By Country, 2017–2027

8.4.1. China

8.4.2. India

8.4.3. ASEAN

8.4.4. Australia and New Zealand

8.4.5. Rest of APEJ

8.5. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

8.5.1. Standard API

8.5.2. High Potency API

8.6.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

8.6.1. Standard API

8.6.2. High Potency API

8.7. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

8.7.1. In-House

8.7.2. Outsourced 

8.8. Market Size (US$ Mn)  Forecast By Production, 2017–2027

8.8.1. In-House

8.8.2. Outsourced 

8.9. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

8.9.1. Clinical 

8.9.2. Commercial 

8.10. Market Size (US$ Mn)  Analysis By Application, 2017–2027

8.10.1. Clinical 

8.10.2. Commercial 

8.11. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

8.11.1. Cardiovascular

8.11.2. Respiratory

8.11.3. Infectious

8.11.4. Metabolic

8.11.5. Oncology

8.11.6. Immunology

8.11.7. Neurology

8.11.8. Urology

8.11.9. Dermatology

8.11.10. Ophthalmology

8.11.11. General Health

8.11.12. Others

8.12.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

8.12.1. Cardiovascular

8.12.2. Respiratory

8.12.3. Infectious

8.12.4. Metabolic

8.12.5. Oncology

8.12.6. Immunology

8.12.7. Neurology

8.12.8. Urology

8.12.9. Dermatology

8.12.10. Ophthalmology

8.12.11. General Health

8.12.12. Others

8.13. Drivers and Restraints: Impact Analysis

8.14. Market Attractiveness Analysis

8.14.1. By Country

8.14.2. By Molecule Type

8.14.3. By Production

8.14.4. By Application

8.14.5. By Therapeutic Area

8.15. Key Representative Market Participants

8.16. Market Presence (Intensity Map)

9. Japan Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

9.1. Introduction

9.2. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

9.2.1. Standard API

9.2.2. High Potency API

9.3.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

9.3.1. Standard API

9.3.2. High Potency API

9.4. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

9.4.1. In-House

9.4.2. Outsourced 

9.5. Market Size (US$ Mn)  Forecast By Production, 2017–2027

9.5.1. In-House

9.5.2. Outsourced 

9.6. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

9.6.1. Clinical 

9.6.2. Commercial 

9.7. Market Size (US$ Mn)  Analysis By Application, 2017–2027

9.7.1. Clinical 

9.7.2. Commercial 

9.8. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

9.8.1. Cardiovascular

9.8.2. Respiratory

9.8.3. Infectious

9.8.4. Metabolic

9.8.5. Oncology

9.8.6. Immunology

9.8.7. Neurology

9.8.8. Urology

9.8.9. Dermatology

9.8.10. Ophthalmology

9.8.11. General Health

9.8.12. Others

9.9.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

9.9.1. Cardiovascular

9.9.2. Respiratory

9.9.3. Infectious

9.9.4. Metabolic

9.9.5. Oncology

9.9.6. Immunology

9.9.7. Neurology

9.9.8. Urology

9.9.9. Dermatology

9.9.10. Ophthalmology

9.9.11. General Health

9.9.12. Others

9.10. Drivers and Restraints: Impact Analysis

9.11. Market Attractiveness Analysis

9.11.1. By Molecule Type

9.11.2. By Production

9.11.3. By Application

9.11.4. By Therapeutic Area

9.12. Key Representative Market Participants

9.13. Market Presence (Intensity Map)

10. Middle East & Africa Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

10.1. Introduction

10.2. Historical Market Size (US$ Mn)  Trend Analysis By Country, 2012–2016

10.2.1. GCC Countries

10.2.2. Turkey

10.2.3. Northern Africa

10.2.4. South Africa

10.2.5. Rest of MEA

10.3. Market Size (US$ Mn)  Forecast By Country, 2017–2027

10.3.1. GCC Countries

10.3.2. Turkey

10.3.3. Northern Africa

10.3.4. South Africa

10.3.5. Rest of MEA

10.4. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

10.4.1. Standard API

10.4.2. High Potency API

10.5.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

10.5.1. Standard API

10.5.2. High Potency API

10.6. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

10.6.1. In-House

10.6.2. Outsourced 

10.7. Market Size (US$ Mn)  Forecast By Production, 2017–2027

10.7.1. In-House

10.7.2. Outsourced 

10.8. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

10.8.1. Clinical 

10.8.2. Commercial 

10.9. Market Size (US$ Mn)  Analysis By Application, 2017–2027

10.9.1. Clinical 

10.9.2. Commercial 

10.10. Historical Market Size (US$ Mn) Trend Analysis By Therapeutic Area, 2012–2016

10.10.1. Cardiovascular

10.10.2. Respiratory

10.10.3. Infectious

10.10.4. Metabolic

10.10.5. Oncology

10.10.6. Immunology

10.10.7. Neurology

10.10.8. Urology

10.10.9. Dermatology

10.10.10. Ophthalmology

10.10.11. General Health

10.10.12. Others

10.11.  Market Size (US$ Mn)  Forecast By Therapeutic Area, 2017–2027

10.11.1. Cardiovascular

10.11.2. Respiratory

10.11.3. Infectious

10.11.4. Metabolic

10.11.5. Oncology

10.11.6. Immunology

10.11.7. Neurology

10.11.8. Urology

10.11.9. Dermatology

10.11.10. Ophthalmology

10.11.11. General Health

10.11.12. Others 

10.12. Drivers and Restraints: Impact Analysis

10.13. Market Attractiveness Analysis

10.13.1. By Country

10.13.2. By Molecule Type

10.13.3. By Production

10.13.4. By Application

10.13.5. By Therapeutic Area

10.14. Key Representative Market Participants

10.15. Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape

13.1. Market Structure

13.2. Competition Dashboard

13.3. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)

13.3.1. Johnson Matthey

13.3.2. Siegfried Holding AG

13.3.3.  Pfizer

13.3.4. Sanofi S.A.

13.3.5. Novartis AG,

13.3.6. Bristol-Myers Squibb,

13.3.7. Boehringer Ingelheim GmbH

13.3.8.  GlaxoSmithKline PLC, GILEAD Science Inc.,

13.3.9.  Albany Molecular Research Inc.

13.3.10.  Bachem Holding AG

13.3.11.  PCAS

13.3.12.  Patheon N.V.

13.3.13.  AstraZeneca

13.3.14.  Johnson & Johnson

13.3.15.  Merck & Co, Inc.

13.3.16.  BASF SE

13.3.17. Catalent Inc.

13.3.18. Teva Pharmaceuticals

13.3.19.  F. Hoffmann-La Roche Ltd

13.3.20.  Cambrex Corporation 

13.3.21. GILEAD Science Inc.

14. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Region

14.1. Introduction/Key Findings

14.2. Historical Market Size (US$ Mn)  Trend Analysis By Region, 2012–2016

14.2.1. North America

14.2.2. Latin America

14.2.3. Western Europe

14.2.4. Eastern Europe

14.2.5. Asia Pacific excluding Japan

14.2.6. Japan

14.2.7. Middle East & Africa

14.3. Market Size (US$ Mn)  Forecast By Region, 2017–2027

14.3.1. North America

14.3.2. Latin America

14.3.3. Western Europe

14.3.4. Eastern Europe

14.3.5. Asia Pacific excluding Japan

14.3.6. Japan

14.3.7. Middle East & Africa

14.4. Market Attractiveness Analysis By Region

15. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type

15.1. Introduction/Key Findings

15.2. Historical Market Size (US$ Mn)  Trend Analysis By Molecule Type, 2012–2016

15.2.1. Standard API

15.2.2. High Potency API

15.3.  Market Size (US$ Mn)  Forecast By Molecule Type, 2017–2027

15.3.1. Standard API

15.3.2. High Potency API

15.4. Market Attractiveness Analysis By Molecule Type

16. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Production

16.1. Introduction/Key Findings

16.2. Historical Market Size (US$ Mn)  Trend Analysis By Production, 2012–2016

16.2.1. In-House

16.2.2. Outsourced 

16.3. Market Size (US$ Mn)  Forecast By Production, 2017–2027

16.3.1. In-House

16.3.2. Outsourced 

16.4. Market Attractiveness Analysis By Application

17. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Application

17.1. Introduction/Key Findings

17.2. Historical Market Size (US$ Mn)  Trend Analysis By Application, 2012–2016

17.2.1. Clinical 

17.2.2. Commercial 

17.3. Market Size (US$ Mn)  Analysis By Application, 2017–2027

17.3.1. Clinical 

17.3.2. Commercial 

17.4. Market Attractiveness Analysis By Application

18. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027, Therapeutic Area

18.1. Introduction/Key Findings

18.2. Historical Market Size (US$ Mn)  Trend Analysis By Therapeutic Area, 2012–2016

18.2.1. Cardiovascular

18.2.2. Respiratory

18.2.3. Infectious

18.2.4. Metabolic

18.2.5. Oncology

18.2.6. Immunology

18.2.7. Neurology

18.2.8. Urology

18.2.9. Dermatology

18.2.10. Ophthalmology

18.2.11. General Health

18.2.12. Others

18.3. Market Size (US$ Mn)  Analysis By Therapeutic Area, 2017–2027

18.3.1. Cardiovascular

18.3.2. Respiratory

18.3.3. Infectious

18.3.4. Metabolic

18.3.5. Oncology

18.3.6. Immunology

18.3.7. Neurology

18.3.8. Urology

18.3.9. Dermatology

18.3.10. Ophthalmology

18.3.11. General Health

18.3.12. Others

18.4. Market Attractiveness Analysis By Therapeutic Area

19. Global Small Molecule Active Pharmaceutical Ingredient Market Analysis 2012–2016 and Forecast 2017–2027

19.1. Market Size and Y-o-Y Growth

19.2. Absolute $ Opportunity

Small Molecule Api Market Reports - List of Tables

Table 01: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 02: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 03: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 04: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 05: North America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 06: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 07: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 08: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 09: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 10: Western Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 11: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 12: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 13: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 14: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 15: Eastern Europe Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 16: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 17: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 18: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 19: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 20: Latin America Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 21: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 22: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 23: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 24: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 25: APEJ Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 26: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 27: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 28: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 29: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 30: MEA Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 31: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 32: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 33: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 34: Japan Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 35: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Molecule Type 

Table 36: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Production

Table 37: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 38: Global Small Molecule API Market Size (US$ Mn) Trend Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Small Molecule Api Market Reports - List of Figures

Figure 01: North America Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 02: North America Small Molecule API Market Forecast, 2017–2017

Figure 03: North America Standard API Historical Market Size Analysis, 2012–2016

Figure 04: North America Standard API Market Forecast, 2017–2017

Figure 05: North America High Potency API Historical Market Size Analysis, 2012–2016

Figure 06: North America High Potency API Market Forecast, 2017–2017

Figure 07: North America Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 08: North America Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 09: North America Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 10: North America Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 11: North America Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 12: North America Small Molecule API Market Forecast by Clinical, 2017–2017

Figure 13: North America Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 14: North America Small Molecule API Market Forecast by Commercial, 2017–2017

Figure 15: North America Small Molecule API Market Attractiveness Analysis, By Country

Figure 16: North America Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 17: North America Small Molecule API Market Attractiveness Analysis, By Production

Figure 18: North America Small Molecule API Market Attractiveness Analysis, Application

Figure 19: North America Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 20: Western Europe Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 21: Western Europe Small Molecule API Market Forecast, 2017–2017

Figure 22: Western Europe Standard API Historical Market Size Analysis, 2012–2016

Figure 23: Western Europe Standard API Market Forecast, 2017–2017

Figure 24: Western Europe High Potency API Historical Market Size Analysis, 2012–2016

Figure 25: Western Europe High Potency API Market Forecast, 2017–2017

Figure 26: Western Europe Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 27: Western Europe Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 28: Western Europe Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 29: Western Europe Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 30: Western Europe Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 31: Western Europe Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 32: Western Europe Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 33: Western Europe Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 34: Western Europe Small Molecule API Market Attractiveness Analysis, By Country

Figure 35: Western Europe Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 36: Western Europe Small Molecule API Market Attractiveness Analysis, By Production

Figure 37: Western Europe Small Molecule API Market Attractiveness Analysis, Application

Figure 38: Western Europe Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 39: Eastern Europe Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 40: Eastern Europe Small Molecule API Market Forecast, 2017–2017

Figure 41: Eastern Europe Standard API Historical Market Size Analysis, 2012–2016

Figure 42: Eastern Europe Standard API Market Forecast, 2017–2017

Figure 43: Eastern Europe High Potency API Historical Market Size Analysis, 2012–2016

Figure 44: Eastern Europe High Potency API Market Forecast, 2017–2017

Figure 45: Eastern Europe Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 46: Eastern Europe Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 47: Eastern Europe Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 48: Eastern Europe Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 49: Eastern Europe Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 50: Eastern Europe Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 51: Eastern Europe Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 52: Eastern Europe Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 53: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Country

Figure 54: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 55: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Production

Figure 56: Eastern Europe Small Molecule API Market Attractiveness Analysis, Application

Figure 57: Eastern Europe Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 58: Latin America Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 59: Latin America Small Molecule API Market Forecast, 2017–2017

Figure 60: Latin America Standard API Historical Market Size Analysis, 2012–2016

Figure 61: Latin America Standard API Market Forecast, 2017–2017

Figure 62: Latin America High Potency API Historical Market Size Analysis, 2012–2016

Figure 63: Latin America High Potency API Market Forecast, 2017–2017

Figure 64: Latin America Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 65: Latin America Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 66: Latin America Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 67: Latin America Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 68: Latin America Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 69: Latin America Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 70: Latin America Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 71: Latin America Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 72: Latin America Small Molecule API Market Attractiveness Analysis, By Country

Figure 73: Latin America Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 74: Latin America Small Molecule API Market Attractiveness Analysis, By Production

Figure 75: Latin America Small Molecule API Market Attractiveness Analysis, Application

Figure 76: Latin America Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 77: APEJ Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 78: APEJ Small Molecule API Market Forecast, 2017–2017

Figure 79: APEJ Standard API Historical Market Size Analysis, 2012–2016

Figure 80: APEJ Standard API Market Forecast, 2017–2017

Figure 81: APEJ High Potency API Historical Market Size Analysis, 2012–2016

Figure 82: APEJ High Potency API Market Forecast, 2017–2017

Figure 83: APEJ Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 84: APEJ Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 85: APEJ Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 86: APEJ Small Molecule API Market Forecast By Outsourced, 2017–2017

Figure 87: APEJ Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 88: APEJ Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 89: APEJ Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 90: APEJ Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 91: APEJ Small Molecule API Market Attractiveness Analysis, By Country

Figure 92: APEJ Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 93: APEJ Small Molecule API Market Attractiveness Analysis, By Production

Figure 94: APEJ Small Molecule API Market Attractiveness Analysis, Application

Figure 95: APEJ Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 96: MEA Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 97: MEA Small Molecule API Market Forecast, 2017–2017

Figure 98: MEA Standard API Historical Market Size Analysis, 2012–2016

Figure 99: MEA Standard API Market Forecast, 2017–2017

Figure 100: MEA High Potency API Historical Market Size Analysis, 2012–2016

Figure 101: MEA High Potency API Market Forecast, 2017–2017

Figure 102: MEA Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 103: MEA Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 104: MEA Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 105: MEA Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 106: MEA Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 107: MEA Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 108: MEA Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 109: MEA Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 110:  MEA Small Molecule API Market Attractiveness Analysis, By Country

Figure 111:  MEA Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 112:  MEA Small Molecule API Market Attractiveness Analysis, By Production

Figure 113:  MEA Small Molecule API Market Attractiveness Analysis, Application

Figure 114:  MEA Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 115: Japan Small Molecule API Historical Market Size Analysis, 2012–2016

Figure 116: Japan Small Molecule API Market Forecast, 2017–2017

Figure 117: Japan Standard API Historical Market Size Analysis, 2012–2016

Figure 118: Japan Standard API Market Forecast, 2017–2017

Figure 119: Japan High Potency API Historical Market Size Analysis, 2012–2016

Figure 120: Japan High Potency API Market Forecast, 2017–2017

Figure 121: Japan Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 122: Japan Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 123: Japan Small Molecule API Historical Market Size Analysis, By Outsourced, 2012–2016

Figure 124: Japan Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 125: Japan Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 126: Japan Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 127: Japan Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 128: Japan Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 129: Japan Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 130: Japan Small Molecule API Market Attractiveness Analysis, By Production

Figure 131: Japan Small Molecule API Market Attractiveness Analysis, Application

Figure 132: Japan Small Molecule API Market Attractiveness Analysis, By Therapeutic Area

Figure 133: Global Small Molecule API Market Size Analysis, 2012–2016

Figure 134: Global Small Molecule API Market Forecast, 2017–2017

Figure 135: Global Standard API Historical Market Size Analysis, 2012–2016

Figure 136: Global Standard API Market Forecast, 2017–2017

Figure 137: Global High Potency API Historical Market Size Analysis, 2012–2016

Figure 138: Global High Potency API Market Forecast, 2017–2017

Figure 139: Global Small Molecule API Historical Market Size Analysis, By In-House, 2012–2016

Figure 140: Global Small Molecule API Market Forecast, By In-House, 2017–2017

Figure 141: Global Small Molecule API Historical Market Size Analysis By, Outsourced, 2012–2016

Figure 142: Global Small Molecule API Market Forecast, By Outsourced, 2017–2017

Figure 143: Global Small Molecule API Historical Market Size Analysis, By Clinical, 2012–2016

Figure 144: Global Small Molecule API Market Forecast, By Clinical, 2017–2017

Figure 145: Global Small Molecule API Historical Market Size Analysis, By Commercial, 2012–2016

Figure 146: Global Small Molecule API Market Forecast, By Commercial, 2017–2017

Figure 147: Global Small Molecule API Market Attractiveness Analysis, By Country

Figure 148: Global Small Molecule API Market Attractiveness Analysis, By Molecule Type

Figure 149: Global Small Molecule API Market Attractiveness Analysis, By Production

Figure 150: Global Small Molecule API Market Attractiveness Analysis, Application

Figure 151: Global Small Molecule API Market Attractiveness Analysis, By Therapeutic Area